floxuridine / Generic mfg. - LARVOL DELTA

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - P3 | N=408 | Recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial completion date: Jun 2034 ➔ Jun 2029

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P1 trial • Colorectal Cancer • Oncology • Solid Tumor • PD-L1

Locoregional therapies for intrahepatic cholangiocarcinoma: a stage-stratified, biology-informed multidisciplinary framework-a narrative review. (PubMed, Chin Clin Oncol) - "LRTs have evolved from salvage interventions to integral components of multidisciplinary iCCA care. Stage-stratified, biology-informed selection and integration with modern systemic backbones offer the most promising path forward. Prospective, modality-stratified trials with standardized endpoints are needed to translate promising signals into evidence-based practice."

Journal • Review • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

N-acetylcysteine partially mitigates floxuridine-induced cytotoxicity in stem cholangiocytes (ACS-CLINCON 2026) - "Abstract is embargoed at this time."

Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy. (PubMed, Adv Sci (Weinh)) - "Here, we leverage ribonucleotides to amplify floxuridine (FUDR)-induced mtDNA release and cGAS-STING activation for enhanced cancer chemoimmunotherapy...FC-NPs robustly activated STING-dependent antitumor immunity, achieving remarkable therapeutic efficacy in multiple murine colorectal cancer (CRC) models. Our study not only addresses the long-standing issue of fluoropyrimidine metabolic instability but also reveals a novel ribonucleotide-mediated immunomodulatory mechanism, providing a promising strategy to potentiate chemoimmunotherapy in CRC."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CMPK1 • IFNB1 • STING

Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial. (PubMed, Eur J Cancer) - P3 | "While our study showed no significant difference in three-year RFS, adjuvant chemotherapy intensification with HAI-FUDR is feasible and may offer early benefits in RFS and long-term OS. Nonetheless, a larger sample size is needed for validation and identifying which patient subgroup might benefit from this regimen."

Journal • Colorectal Cancer • Hepatology • Oncology • Solid Tumor • BRAF

The use of locoregional therapies in cholangiocarcinoma. (PubMed, J Hepatol) - "Other trials have analysed external beam radiotherapy (EBRT), often using high-precision techniques (3-year OS 38%), as well as intra-arterial therapies, including transarterial chemoembolisation (3-year OS 17%), selective internal radioembolisation (3-year OS 40%), and floxuridine delivery through a hepatic arterial infusion pump (3-year OS 26-50%)...Until further evidence from randomised controlled trials becomes available, treatment strategies for patients with unresectable or advanced CCA should be individualised, incorporating flexible, staged combinations of locoregional and systemic therapies within a personalised therapeutic framework. These decisions should be made within a multidisciplinary tumour board."

Journal • Review • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • Transplantation

Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial. (ASCO 2026) - P=N/A | "In patients with resectable CLM and a low CRS, no improvement in PFS after adjuvant HAIP chemotherapy with floxuridine compared to resection alone could be demonstrated. Mature results for overall survival are expected in 2029. EudraCT number: 2018-001696-21."

Clinical • Late-breaking abstract • Hepatology

Caenorhabditis Intervention Testing Program: all-trans retinoic acid lifespan extension in Caenorhabditis elegans requires 5-Fluoro-2'-deoxyuridine (FUdR). (PubMed, MicroPubl Biol) - "Here, we show that FUdR enhances atRA's lifespan effects, but that this potentiation is not simply due to progeny elimination, as sterilization through auxin-mediated disruption of spermatogenesis does not potentiate atRA in lifespan extension. We conclude that atRA longevity is dependent on additional effects of FUdR that remain uncharacterized."

Journal

A simplified intermittent fasting regimen robustly extends C. elegans lifespan without FUdR or antibiotic confounds. (PubMed, bioRxiv) - "Daily intermittent fasting robustly extended lifespan by 24-57%, demonstrating that repeated fasting windows during adulthood are sufficient to promote longevity under minimally confounded conditions. These findings establish a straightforward and experimentally tractable intermittent fasting paradigm for C. elegans and underscore the importance of limiting pharmacological and microbial conditions in dietary-intervention experiments."

Journal

HAIP-6192: Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Sunnybrook Health Sciences Centre

New P2 trial • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases (clinicaltrials.gov) - P2 | N=14 | Active, not recruiting | Sponsor: Corewell Health West | Trial completion date: Dec 2025 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2028

Trial completion date • Trial primary completion date • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Repurposed anticancer drugs disrupt cancer-like traits of Theileria annulata and suppress Leishmania donovani. (PubMed, Cell Commun Signal) - "Notably, floxuridine, masitinib, paclitaxel, cabazitaxel, vinorelbine, maytansine, and bortezomib also suppressed L. donovani, highlighting cross-species efficacy. Target mapping revealed that the majority of active molecules disrupt hallmarks of cancer and parasite-transformed cells, including metabolic reprogramming, genome instability, and invasive phenotypes. Collectively, these findings underscore the value of oncology-derived drug libraries for antiparasitic discovery and identify promising candidates for further evaluation against T. annulata and L. donovani."

Journal • Infectious Disease • Oncology

HELIX-ICC: mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - P2 | N=5 | Terminated | Sponsor: OHSU Knight Cancer Institute | Active, not recruiting ➔ Terminated; change in standard-of-care systemic therapy

Trial termination • Biliary Cancer • Cholangiocarcinoma • Liver Cancer • Oncology • Solid Tumor

Study protocol: targeted delivery of interleukin-12 in combination with hepatic artery infusion pump therapy for patients with adrenocortical carcinoma liver metastases. (PubMed, BMC Cancer) - P2 | "For select patients with ACC liver metastasis, HAIP therapy with PDS01ADC may improve disease control and thereby prolong survival."

Journal • Adrenal Cortex Carcinoma • Genito-urinary Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • IL12A

Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials. (PubMed, J Hepatol) - "Patients with unresectable, liver-confined iCCA who underwent HAIP with systemic chemotherapy had a 3-year OS rate of 28% and 5-year OS rate of 15% across four phase II trials. These results provide long-term benchmark results for a selected patient population."

Journal • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Hepatology • Oncology • Solid Tumor

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - P2 | N=64 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 ➔ May 2027 | Trial primary completion date: May 2025 ➔ May 2027

Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT. (PubMed, BMC Cancer) - P3 | "The PUMP-IT RCT is the first prospective randomised trial to investigate HAIP-SYST as first line treatment for initially unresectable CRLM. This Dutch multicentre trial is open for accrual as of November 2024."

Journal • Colorectal Cancer • Hepatology • Oncology • Solid Tumor

CRISPR/Cas9 Recombineering with Bacteriophage Recombinases Enables Efficient and Scarless Genome Editing in Cupriavidus necator H16. (PubMed, ACS Synth Biol) - "To facilitate rapid multiround engineering, we integrated a tdk-based counterselection marker into the sgRNA plasmid, reducing plasmid-retaining cells to 1.1% within 24 h under 5-fluoro-2'-deoxyuridine (FUDR) selection. Overall, this streamlined toolkit enables efficient, iterative, and scarless genome editing in C. necator, accelerating C. necator strain development for C1 metabolic engineering and industrial applications."

Journal

The Excessive, Opportunistic Price Increase of Generic Oncology Drug Floxuridine. (PubMed, J Cancer Policy) - "As floxuridine becomes more widely available through ongoing clinical trials, concerns about its affordability and financial toxicity will be difficult to ignore. Floxuridine serves as a cautionary tale of how niche-market generics can evade public scrutiny while imposing unnecessary costs on our healthcare system."

Journal • Oncology

Relaxation Suppressed Exchange Tuning MRI Integrated with Manganese-Based Nanozyme Probes for Ferroptosis Induction and GPX4 Monitoring. (PubMed, ACS Appl Bio Mater) - "ReSET was achieved by a tumor-microenvironment-responsive nanoprobe (SiO2@FUDR@MnO2, SiFM), consisting of a mesoporous silica core loaded with chemotherapeutic floxuridine and the MnO2 shell with nanozyme activities...Meanwhile, we revealed that the ReSET strategy enables sensitive detection of small lesions in liver micrometastasis models. Overall, we establish a ReSET MRI-guided strategy using a manganese-based nanoplatform, which represents a promising ferroptosis-related theranostic approach for TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • GPX4

Tumor-Targeted IL-12 (PDS01ADC) with Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Non-randomized Phase II Trial. (PubMed, JCO Oncol Adv) - P2 | "NCT05286814 is a phase II non-randomized trial evaluating subcutaneous PDS01ADC in combination with HAIP floxuridine and systemic chemotherapy (FOLFOX or FOLFIRI) in patients with unresectable microsatellite stable or mismatch repair-proficient colorectal liver metastases previously treated with at least one line of systemic chemotherapy...Addition of PDS01ADC is not detrimental to HAIP therapy and is associated with both systemic and intratumoral immune modulation. Initial results warrant continuation to full enrollment for further evaluation of clinical and scientific endpoints."

Journal • P2 data • Colorectal Cancer • Immune Modulation • Immunology • Oncology • Solid Tumor • CD8 • IL12A

Do drugs with biliary toxicity cause cholangiocarcinoma? (PubMed, bioRxiv) - "Furthermore, we analyzed the CCA incidence in our healthcare system and determined it to be 0.0932% (Augmentin group) and 0.0799% (amoxicillin control group). Similarly, we found no evidence for cholangiocarcinoma development with other commonly used drugs, including chlorpromazine, floxuridine, 5-fluorouracil, flucloxacillin and terbinafine. We conclude that there is no direct causal relationship between clinical Augmentin doses and CCA development."

Journal • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • YAP1

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery (clinicaltrials.gov) - P2 | N=164 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 ➔ May 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Hepatic Artery Infusion Pump Chemotherapy Associated Biliary Sclerosis After Treatment for Colorectal Cancer Liver Metastasis. (PubMed, Ann Surg Oncol) - "The incidence of BS after HAIC for CRLM is 6% after 60 months and does not differ in the adjuvant and unresectable setting due to meaningful differences in survival. Cumulative floxuridine dose and number of HAIC cycles were independently associated with increased BS risk."

Journal • Colorectal Cancer • Oncology • Solid Tumor